**Final[[1]](#footnote-2) project report - Template**

**[Full Project Title]**

**[Acronym]**

**[Grant Agreement No]**

**[Name of the scientific representative of the Coordinator][[2]](#footnote-3)**

[Coordinator Institution]

[Coordinator Contact Details]

Last Period [month/year] - [month/year]

Reporting Period [number]

Duration of the project [start project month/year] - [end project month/year]

Description of work - [date/version]

Submission deadline

[Declaration of the coordinator 3](#_Toc445907180)

[1. Executive summary 4](#_Toc445907181)

[1.1. Project rationale and overall objectives of the project 4](#_Toc445907182)

[1.2. Overall deliverables of the project 4](#_Toc445907183)

[1.3. Summary of progress versus plan since last period 4](#_Toc445907184)

[1.4. Significant achievements since last report 4](#_Toc445907185)

[1.5. Scientific and technical results/foregrounds of the project 4](#_Toc445907186)

[1.6. Potential impact and main dissemination activities and exploitation of results 4](#_Toc445907187)

[1.7. Lessons learned and further opportunities for research 4](#_Toc445907188)

[2. Summary of progress against objectives 5](#_Toc445907189)

[2.1. Summary table 5](#_Toc445907190)

[2.2. Description of progress for delayed milestones/deliverables not completed partially completed during the last reporting period 5](#_Toc445907191)

[2.3. Follow-up of recommendations and comments from previous review(s) (if applicable) 5](#_Toc445907192)

[2.4. Deviations from Description of Work during the last reporting period 5](#_Toc445907193)

[2.5. Summary statement on all Work Packages 6](#_Toc445907194)

[3. Summary of Major Achievements and key dissemination activities 7](#_Toc445907195)

[3.1. Major achievements for the last reporting period 7](#_Toc445907196)

[3.2. Key dissemination activities for the last reporting period 7](#_Toc445907197)

[4. Summary of project outcomes 7](#_Toc445907198)

[5. Research use and dissemination of Foreground 14](#_Toc445907199)

[5.1. Current Status 14](#_Toc445907200)

[5.2. Plan for Research use and dissemination of Foreground 14](#_Toc445907201)

[5.3. Plan for sustainability 19](#_Toc445907202)

[6. Management of Project and Consortium 19](#_Toc445907203)

[7. Finance - Cost 20](#_Toc445907204)

[7.1. Cost summary for the last reporting period 20](#_Toc445907205)

[7.2. Description of deviation from original budget 22](#_Toc445907206)

[8. Form C and Summary Financial Report 23](#_Toc445907207)

Declaration of the coordinator

I, the coordinator of this project, declare that,

The final report submitted is in line with the obligations as stated in Article II.2.3 of the Grant Agreement:

The attached report represents an accurate description of the work carried out in this project for the last reporting period as well as for the whole duration of the project;

For the last period, the project *(tick as appropriate):*

* has fully achieved its objectives and technical goals; has achieved most of its objectives and technical goals for the period with relatively minor deviations[[3]](#footnote-4);
* has failed to achieve critical objectives and/or is not at all on schedule3.

For the whole duration of the project, the project *(tick as appropriate):*

* has fully achieved its objectives and technical goals;
* has achieved most of its objectives and technical goals with relatively minor deviations3;
* has failed to achieve critical objectives and/or is not at all on schedule3.

The public project website <address>[[4]](#footnote-5) is up to date.

To my best knowledge, the financial statements which are being submitted as part of this final report are in line with the actual work carried out and are consistent with the report on the resources used for the project (section 7) and if applicable with the certificate on financial statement.

All participants, in particular non-profit public bodies, secondary and higher education establishments, research organisations and SMEs, have declared to have verified their legal status. Any changes or deviations have been reported under section 6 (Project Management) in accordance with Article II.3.f of the Grant Agreement.

Name of the Coordinator: ……………………………………………………

Date: ............/ ............/ ............

Signature of the Coordinator: …………………………………………..….

1. Executive summary

The executive summary will be made publically available, and therefore should not include information deemed as confidential by the consortium. It should be concise (preferably no more than 40 pages), comprehensive and should capture the updates for the last reporting period as well as the overall outputs of the project and its impact. It shall at least cover the following items**:**

## Project rationale and overall objectives of the project

(max 1 page)

## Overall deliverables of the project

(max 1 page)

## Summary of progress versus plan since last period

 (Any major deviations, risks should be highlighted in this section)

## Significant achievements since last report

## Scientific and technical results/foregrounds of the project

## Potential impact and main dissemination activities and exploitation of results

Please explain how the project scientific/technical outputs contribute to the overall IMI objectives:

* to provide socio-economic benefits for European citizens,
* to contribute to the health of European citizens,
* to increase the competitiveness of Europe and help to establish Europe as the most attractive place for biopharmaceutical research and development.

Please outline how the project outputs have/will have the potential to be rapidly and broadly spread and taken up within the scientific/industrial community and healthcare professionals.

## Lessons learned and further opportunities for research

Please indicate how the collaboration in a public private partnership (PPP) has been an added value to achieve the objectives of the project.

From your experience, please propose any recommendations/ solutions which could be useful for a PPP.

In view of your project achievements, please provide your views on potential new research to further advance the field.

1. Summary of progress against objectives

## 2.1. Summary table

Please include the complete list of all milestones and deliverables of the project including those due for the last reporting period, and any outstanding ones from the previous reporting period(s). Description of the milestones/deliverables should be short and concise reflecting the status.

Please align these milestones and deliverables with the objectives listed above.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Work -Package Number** | **Milestone/****Deliverable** | **Due Date****(Annex I- description of work)** | **Completed****(Yes/Not yet/Partially)** | **Dissemin. level[[5]](#footnote-6)** | **Related document attached****(Yes/No/Not applicable)** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

## **2.2.** **Description of progress for delayed milestones/deliverables not completed** partially completed during the last reporting period

For those milestones and deliverables “not completed-partially completed” for the last reporting period, please explain the reasons for non-completion and the impact on achieving the overall objectives of the project. Description should be no more than 1/2 page for each milestone/deliverable.

[No further description is needed for the completed milestones/deliverables for which related document(s) listed in the table above has been provided].

* 1. **Follow-up of recommendations and comments from previous review(s) (if applicable)**

Include in this section the list of recommendations and comments from previous reviews and give information on how they have been followed up.

* 1. **Deviations from Description of Work during the last reporting period**

(max 2 pages)

In case of any major deviations during the last reporting period, please provide the reason for such deviations as well as measures taken to achieve the objectives of the project. Please focus on major deviations which impact on success of the project, including budget.

* 1. Summary statement on all Work Packages

For this final report, please provide a summary statement for each work package (max 3 pages for work-package). In case of major deviations, please explain.

1. Summary of Major Achievements and key dissemination activities

##  Major achievements for the last reporting period

(max 1 page)

For the last reporting period, please present the major achievements that really capture the impact of your project in adding to the knowledge in this research area using tangible results.

Achievements should be described as a standalone success for the project e.g. major results in publications, successful ‘qualification for use’ approval, successful course launch/completion as well as feedback from attendees and raising awareness of patients.

Please avoid repeating progress against milestones and deliverables.

These major achievements may be used by the IMI JU to communicate success stories.

##  Key dissemination activities for the last reporting period

Please report major activities undertaken during the last reporting period to disseminate the project results including patent application, publications, abstracts, conferences, project website using the table below and specify for each activity the target group (e.g. scientific community, patients’ organisations, policy makers, the general public).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nature of Communication**  | **Title**  | **Responsible Participant** | **Date** | **Target audience**  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

1. Summary of project outcomes

Please fill the below table for your project. Some sections of the form may not be relevant to your project. The information on your project will provide IMI with statistics and indicators on societal and socio-economic issues addressed by projects. It will help to feed Key Performance Indicators (KPIs) for the measurement of performance and results against strategic overarching priorities identified as critical for overall success of IMI. The replies for individual project will not be made public.

Where appropriate please document the resources produced by the project (with the exclusion of deliverable reports and publications) and where they are archived for the purpose of reproducibility/verifiability. If the resource is destroyed (e.g. bio samples) please indicate.

|  |
| --- |
| 4.1. Project general information |
| Research area |  |
| Type of impact | *Methodology, model, tool, process, drug etc.* |
| Stage in drug development pathway | *Lead discovery, lead optimisation, Pre-clinical, clinical, manufacturing, etc.* |
| 4.2. Staff statistics |
| Please indicate in the table below the number of people who worked on the project (on a headcount basis). |
| **Type of position** | **Number of Women** | **Number of Men** |
| Scientific Coordinator |  |  |
| Work Package leaders |  |  |
| Experienced researchers (i.e. PhD holders) |  |  |
| PhD Students |  |  |
| Other |  |  |
| Number of personnel hired for the project |  |  |
| Number of staff changing positions within and between partners (staff mobility) | *Specify organisations* | *Specify organisations* |
| 4.3. Resource Input from the Project Partners |
|  | **Number of resources pooled** | **Size** | **Unit**(data, samples subjects, compounds, etc.) | **Comments** |
| Data sets[[6]](#footnote-7) |  |  |  | *Briefly describe resource* |
| Biobanks[[7]](#footnote-8) |  |  |  | *Briefly describe resource* |
| Biologicals Samples[[8]](#footnote-9) |  |  |  | *Briefly describe resource* |
| Cohorts[[9]](#footnote-10)/ Patient registries[[10]](#footnote-11) |  |  |  | *Briefly describe resource* |
| Software[[11]](#footnote-12) |  |  |  | *Briefly describe resource* |
| Models, tools |  |  |  | *Briefly describe resource* |
| Compounds |  |  |  | *Briefly describe resource* |
| Other (please specify) |  |  |  | *Briefly describe resource* |

|  |
| --- |
| 4.4. Resource Outputs of the project |
| **Models, tools, technologies, molecules, protocols** |
|  | **Number/size and type** | **Stage of development** | **Resource location and identifier, future maintenance**Provide unique identifier, DOI or data citation |
| Biomarkers | *Efficacy, safety, prognostic, etc.* | *Identified, validated, qualified, etc.* |  |
| Preclinical models (in vitro) |  | *Standardised, validated, qualified, etc.* |  |
| Preclinical models (in vivo) |  | *Standardised, validated, qualified, etc.* |  |
| In silico models |  | *Standardised, validated, qualified, etc.* |  |
| Tools (diagnostic)/assays  |  | *Standardised, validated, qualified, etc.* |  |
| Patient reported outcomes |  | *Standardised, validated, qualified, etc.* |  |
| Modelling and Simulation technologies |  | *Standardised, validated, qualified, etc.* |  |
| New drug targets |  | *Discovered, validated, qualified, etc.* |  |
| Novel hit and lead molecules |  |  |  |
| Novel clinical protocols  |  |  |  |
| New disease related definitions |  |  |  |
| Other (specify) |  |  |  |
| **Infrastructure (operations)** |
| Patient registries/cohorts | *Number of patients included* |  |  |
| Clinical Networks | *Number of centres* |  |  |
| Biobanks | *Number of samples* |  |  |
| Other (specify) |  |  |  |

|  |
| --- |
| **‘Big data’ solutions to leverage knowledge[[12]](#footnote-13)** |
|  | **Number/size and type** | **Comments / Resource location and identifier, future maintenance**Provide unique identifier, DOI or data citation |
| Databases | *size* | *Data citation including Data model description, data quality description, interoperability through format and content standards* |
| New data collection | *# of studies with new data collection* | *Data Citation* |
| Harmonization of existing data from multiple sources (pooling)  | *# of data fields reviewed and harmonized*  | *Data Citation* |
| Linking different databases (linked data)[[13]](#footnote-14) | *number of data & information sources linked* | *Data Citation* |
| Software applications  | *# deployed /# releases / #newly developed* | *Please specify internal / public**Validated, Data Citation* |
| Mathematical/Statistical Model Repositories for reuse | *# of models curated and loaded* | *Data Citation* |
| Other (specify) |  |  |
| **Implementation of Standards** |
|  | **Number/size and type** | **Comments / Resource location and identifier, future maintenance**Provide unique identifier, DOI or data citation |
| Data Format and Content Standards and Vocabularies (including ontologies)  | *adopted/adapted or developed; references*  | *Data Citation; In collaboration with a standards development organization (e.g. CDISC) Yes/NO**Have the standards and vocabularies been cited in project publications? yes/no* |
| Standard Operating Procedures | *# developed; application area*  | *Data Citation; Are the procedures Findable/ Accessible / Reusable)?* |
| Other (specify) |  |  |

|  |
| --- |
| **Education and Training Programme outputs** |
|  | **Number** | **Comments** |
| Courses conducted |  | *Training type, face to face or e-course, masters, stand alone, etc.* |
| Trainees who completed continuous professional development training programs |  | *Trainee type; EFPIA, academia, regulators, patients* |
| Students graduated from different training programmes |  | *Trainee type; EFPIA, academia, regulators, patients* |
| Teachers involved in the training programmes |  | *Trainee type; EFPIA, academia, regulators, patients* |
| Training centres labelled “excellence” |  |  |
| Countries covered by training centres |  | *List countries* |
| Other (specify) |  |  |
| **Business related outputs** |
|  | **Number** | **Comments** |
| Implementation of project results in industry |  | *Brief description* |
| Patents or other IP rights |  | *Filled, awarded, etc.* |
| Spin offs created or planned |  | *Partners involved, etc.* |
| Buy outs, take overs |  | *Partners involved, etc.* |
| Material Transfer Agreement (MTA), licencing deals with industry |  | *Type of deal and partners involved* |
| Number of additional EFPIA companies and funding attracted (after GA signature) |  | *List entities* |
| Number of additional beneficiaries attracted (after GA signature) |  | *List entities* |
| Additional funding sources and amounts |  |  |
| Other (specify) |  |  |
| **Impact on regulatory framework** |
| Regulators part of the consortium | *Yes or no* | *List entities* |
| Regulators part of advisory board | *Yes or no* | *List entities* |
| Qualification advice completed or in progress | *Yes or no* | *Comments* |
| Qualification opinion completed or in progress | *Yes or no* | *Comments* |
| Impact/input into regulatory practices | *Yes or no* | *Details* |
| **Impact on Health Technology Assessment framework** |
| HTA bodies part of the consortium | *Yes or no* | *List entities* |
| HTA bodies part of advisory board | *Yes or no* | *List entities* |
| HTA opinion completed or in progress | *Yes or no* | *Comments* |
| Impact/input into HTA practices | *Yes or no* | *Comments* |
| **Sustainability plans** |
| Sustainability/business plan in place (yes/no) | *Brief description* |

|  |
| --- |
| 4.5. Stakeholder engagement |
| **SMEs** | **Number** | **Comments** |
| SMEs as consortium partners |  | *Type of SME; research, management, etc.* |
| SMEs created |  | *Size of company created and type* |
| SME growth |  | *Staff hires, opening new sites* |
| **Patient organisations** | **Number** | **Comments** |
| Participation to the consortium |  | *List entities* |
| Participation to the advisory/ethics board |  | *List entities* |
| Consultations at hoc |  | *List entities* |
| **Engagement with healthcare professionals** | **Number** | **Comments** |
| Participation to the consortium |  | *List entities* |
| Participation to the advisory board |  | *List entities* |
| Consultations ad hoc |  | *List entities* |
| 4.6. Collaboration |
|  | **Number** | **Comments** |
| Memoranda of Understanding within IMI |  | *List collaborators* |
| Memoranda of Understanding outside IMI |  | *List collaborators* |
| Staff exchanges and internships |  | *Type; industrial and academic internship* |
| 4.7. Dissemination |
|  | **Number** | **Comments** |
| Publications |  | *How many were open access* |
| Data citation |  |  |
| External newsletter circulated |  |  |
| Presentations at scientific meetings |  | *Type of meeting, audience type, size and country* |
| Website for general public (patients) |  |  |
| Press releases |  |  |
| Media (TV, radio, press, multimedia) |  | *Type of media outlet and target audience* |
| Brochures / posters / flyers |  | *Type of target audience* |

|  |
| --- |
| 4.8. Ethics |
| Did your project undergo an Ethics Review (and/or Screening)? |  |
| If Yes: have you described the progress of compliance with the relevant EthicsReview/Screening |  |
| **RESEARCH ON HUMANS** | **Yes or No** |
| Did the project involve children? |  |
| Did the project involve patients? |  |
| Did the project involve persons not able to give consent? |  |
| Did the project involve adult healthy volunteers? |  |
| Did the project involve Human genetic material? |  |
| Did the project involve Human biological samples? |  |
| Did the project involve Human data collection? |  |
| **RESEARCH ON HUMAN EMBRYO/FOETUS** | **Yes or No** |
| Did the project involve Human Embryos?  |  |
| Did the project involve Human Foetal Tissue / Cells? |  |
| Did the project involve Human Embryonic Stem Cells (hESCs)? |  |
| Did the project on human Embryonic Stem Cells involve cells in culture? |  |
| Did the project on human Embryonic Stem Cells involve the derivation of cells from Embryos? |  |
| **PRIVACY** | **Yes or No** |
| Did the project involve processing of genetic information or personal data (e.g. health, sexual lifestyle, ethnicity, political opinion, religious or philosophical conviction)? |  |
| Did the project involve tracking the location or observation of people? |  |
| **RESEARCH ON ANIMALS** | **Yes or No** |
| Did the project involve research on animals? |  |
| Were those animals transgenic small laboratory animals? |  |
| Were those animals transgenic farm animals? |  |
| Were those animals cloned farm animals? |  |
| Were those animals non-human primates? |  |
| **RESEARCH INVOLVING DEVELOPING COUNTRIES** | **Yes or No** |
| Did the project involve the use of local resources (genetic, animal, plant etc.)? |  |
| Was the project of benefit to local community (capacity building, access to healthcare, education |  |
| **DUAL USE** | **Yes or No** |
| Research having direct military use |  |
| Research having the potential for terrorist abuse |  |

1. Research use and dissemination of Foreground

## 5.1. Current Status

Please describe what has been done in relation to the research use and dissemination of Foreground for the consortium as a whole, or for individual or groups of participant(s) (including socio-economic impact and target groups for the results of the research).

## 5.2. Plan for Research use and dissemination of Foreground

Please present the plan that the consortium has established at the end of the project. The plan should consist of two sections:

* Section A

This section should describe the planned dissemination measures, including any scientific publications relating to Foreground (templates A1 and A2 provided hereafter to be filled in). Its content **will be made available in the public domain** thus demonstrating the added-value and positive impact of the project on IMI.

|  |
| --- |
| **template A1: list of planned scientific (peer reviewed) publications, starting with the most important ones** |
| **NO.** | **Title** | **Main author** | **Title of the periodical or the series** | **Number, date or frequency** | **Publisher** | **Place of publication** | **Year of publication** | **Relevant pages** | **Permanent identifiers[[14]](#footnote-15)****(if available)** | **Is/Will open access[[15]](#footnote-16) provided to this publication?** |
| 1 | *Ex: Economic transformation in Hungary and Poland’* |  | *Ex: European Economy* | *Ex: No x, March 20xx* | *Ex: Office for Official Publications of the European Communities* | *Ex: Luxembourg* | *Ex: 20xx* | *Ex: pp. 151 - 167* |  | yes/no |
| 2 |  |  |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |  |  |

|  |
| --- |
| **template A2: list of planned dissemination activities** |
| **NO.** | **Type of activities**[[16]](#footnote-17) | **Main leader** | **Title** | **Date/Period**  | **Place**  | **Type of audience**[[17]](#footnote-18) | **Size of audience** | **Countries addressed** |
| 1 | *Ex: Conference* |  | *Ex: European Conference on Nanotechnologies* | *Ex: 26 February 20xx* |  |  |  |  |
| 2 |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |

* Section B

This section should specify the exploitable Foreground and provide the plans for exploitation. All these data can be public or confidential; the report must clearly mark non-publishable (confidential) parts that will be treated as such by IMI. Information that is not marked clearly as confidential **will be made available in the public domain** thus demonstrating the added-value and positive impact of the project on IMI.

The applications for patents, trademarks, registered designs, etc. shall be listed according to the template B1 provided hereafter.

The list should specify at least one unique identifier e.g. European Patent application reference. For patent applications, only if applicable, contributions to standards should be specified. This table is cumulative, which means that it should always show all applications from the beginning until after the end of the project.

Exploitable Foreground shall be listed according to the template B2 provided hereafter. In addition to the table (template B2), please explain the exploitable Foreground, in particular:

* How the Foreground might be exploited, when and by whom, including IPR measures taken or intended,
* Further research necessary, if any,
* Potential/expected impact (quantify where possible).

|  |
| --- |
| **Template B1: list of applications for patents, trademarks, registered designs, etc.** |
| **Type of IP Rights[[18]](#footnote-19)** | **Confidential****Click on YES/NO** | **Foreseen embargo date****dd/mm/yyyy** | **Application reference(s) (e.g. EP123456)** | **Subject or title of application** | **Applicant (s) (as on the application)** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

|  |
| --- |
| **Template B2: exploitable foreground** |
| **Type of Exploitable Foreground[[19]](#footnote-20)** | **Description****of exploitable Foreground** | **Confidential****Click on YES/NO** | **Foreseen embargo date****dd/mm/yyyy** | **Exploitable product(s) or measure(s)** | **Sector(s) of application[[20]](#footnote-21)** | **Timetable, commercial or any other use** | **Patents or other IPR exploitation (licences)** | **Owner & Other Beneficiary(s) involved** |
|  | *Ex: New superconductive Nb-Ti alloy* |  |  | *Ex: MRI equipment* | *Ex Medical* | *Ex 20xx**20xx* | *Ex A materials patent is planned for 2006* | *Ex Beneficiary X (owner)**Beneficiary Y, Beneficiary Z, Poss. licensing to equipment manuf. ABC* |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

## 5.3. Plan for sustainability

Please indicate the actions taken to ensure the sustainability beyond the end of the project, when relevant.

1. Management of Project and Consortium

(max 0.5 page)

Please describe the overall management of the project during the period, highlighting any success factors and/or challenges that have arisen within the team and indicate how these challenges have been resolved.

Throughout the lifetime of the project, summarise, if any, the major changes in the composition of the consortium, and in case these have created difficulties for the progress of the project, please explain the approach taken to resolve them.

Please indicate if any interactions, synergies with other IMI projects or any other relevant programmes occurred during the period.

Please describe if any interactions with relevant stakeholders occurred during the period or are foreseen, including Regulators, Health Technology Assessment Bodies and patients organisations.

In particular, when relevant, please indicate if the consortium has taken any actions to interact with the Regulators in the context of qualification advice/opinion procedures.

Please comment on the aspects related to the public private partnership (PPP) during the period
i.e. added value of the collaboration on the project or leverage effect if any.

1. Finance - Cost

## 7.1. Cost summary for the last reporting period

Please provide a cost summary for the last reporting period by filling the following tables (one table per participant; for adjustment to previous periods a separate table should be added per adjusted period).

Any deviations from original budget should be highlighted and explanation given in section 7.2.

* **Reporting of costs incurred by IMI beneficiaries and third parties**

Please note that the table may also be used to report costs declared by participant special clause 11 (participant which are neither a beneficiary nor an EFPIA company).

|  |
| --- |
| **Table: Personnel and other major cost items including subcontracting** |
| **[Beneficiary number and name] – [if applicable, adjustment to Period n]** |
| Work relevant to Work- Package(s) | Item description | Amount in € | Explanations of the use of resources |
|  | **Personnel direct costs** |  | *e.g. salaries of 2 postdoctoral students 6PM each, or 50% each* |
|  | **Subcontracting** *[if foreseen in Description of Work]* |  |  |
|  | **Other direct costs** |  |  |
|  | *Consumables [if applicable]* |  |  |
|  | *Equipment depreciation[if applicable]* |  | *depreciation of important equipment (provide detail)* |
|  | *Other [if applicable]* |  | *e.g. maintenance of the web site , animal costs* |
|  | **Indirect costs** |  | *e.g. 20% flat rate, actual indirect costs* |
| TOTAL COSTS |  |  |
| Budget for the last period |  |  |
| Deviation |  |  |

**Direct financial contribution**

In case of direct financial contribution (‘’in-cash”) received from EFPIA company(ies), please provide the details of the amounts received as well as the name(s) of the EFPIA company(ies).

* **Reporting of costs incurred by EFPIA companies**

|  |
| --- |
| **Table: Personnel and other major cost items including subcontracting** |
| **[EFPIA participant number and name] – [if applicable, adjustment to Period n]** |
| Work relevant to Work- Package(s) | Item description | Amount in € | Explanations of the use of resources |
|  | **Personnel direct costs** |  | *e.g. salaries of 2 postdoctoral students* |
|  | **Subcontracting** *[if foreseen in Description of Work]* |  |  |
|  | **Other direct costs**  |  |  |
|  | *Consumables [if applicable]* |  |  |
|  | *Equipment depreciation [if applicable]* |  | *depreciation of important equipment (provide detail)* |
|  | *Other [if applicable]* |  | *e.g. maintenance of the web site , animal costs* |
|  | **Indirect costs** |  | *only if not included in FTE, according to certified methodology* |
| Sub-total in kind contribution |  |  |
| Direct financial contribution |  |  |
| Total in kind contribution |  |  |
| ***Of which*** *Non-EU in kind contribution[[21]](#footnote-22)* |  | *Please specify the type of costs* |
| Budget for the last period |  |  |
| Deviation |  |  |

|  |
| --- |
| **Non-EU in kind contribution NOT eligible**[[22]](#footnote-23) |
| Work relevant to Work- Package(s) | Item description | Amount in € | Explanations of the use of resources |
|  | *Major cost item 'Y'* |  |  |

7.2. Description of deviation from original budget

(max 0.5 page)

Please fill-in for each IMI beneficiary and each third party the below table.

|  |
| --- |
| **Beneficiary – Deviation for original budget** |
|  | A1 | A2 | A3**A1+ A2** | B | CA3-B | DA3/B |
| Participant no and name | IMI JU contributionfor the **previous** reporting periods(\*) | IMI JU requested contributionfor the **last** reporting period | Total IMI JU contribution | Budget (IMI contribution)over the project life-time | Deviation | Current budgetStatus |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |
| **Total IMI Contribution** | **Σ IMI contribution** | **Σ IMI contribution** | **Σ IMI contribution** | **Σ Budget** | **Σ deviation** | **A3/B** |

(\*) for previous reporting period: accepted IMI contribution.

Please fill-in for each EFPIA company the below table.

|  |
| --- |
| **EFPIA Company – Deviation for original budget** |
|  | A | A2 | A3**A1+ A2** | B | CA3-B | DA3/B |
| Participant no and name | Cumulativein kindfor the **previous** reporting periods | Cumulativein kindfor the **last** reporting period | Total Cumulativein kind | Cumulative Budgetedin kindover the project life-time | Deviation | Current budgetStatus |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |
| **Total EFPIA in kind** | **Σ in kind** | **Σ in kind** | **Σ in kind** | **Σ Budget** | **Σ deviation** | **A3/B** |

In addition, if any, please explain only the major deviations from original budget for the last reporting period (e.g. redistribution of resources from one participant to another) which has an impact on the overall project.

1. Form C and Summary Financial Report

For the last reporting period:

The following must be submitted as separate PDF files (originals should be sent by surface mail):

* Summary financial report, extracted from SOFIA (Submission OF Information Application),
* Form Cs for each participant (beneficiary, third party, EFPIA companies), extracted from SOFIA,
* Certificate on financial statements[[23]](#footnote-24).

As this is the final report, please note that 30 days after receipt of the final payment the managing entity shall submit a report on the distribution of the IMI JU financial contribution between beneficiaries.

1. The Final project report also includes the periodic report of the last period (see Articles II.4 and II.4.2 of the IMI Model Grant Agreement). [↑](#footnote-ref-2)
2. Usually the person mentioned in the coordinator A2.4 form (in SOFIA IT tool). [↑](#footnote-ref-3)
3. If either of these boxes is ticked, the report should reflect these and any remedial actions taken. [↑](#footnote-ref-4)
4. Please add the address of the public project website. The home page of the website should contain the generic IMI logo which is available in electronic format at the IMI website. The area of activity of the project should also be mentioned. [↑](#footnote-ref-5)
5. PU = Public, fully open, e.g. web CO = Confidential, restricted under conditions set out in Model Grant Agreement CI = Classified, information as referred to in Commission Decision 2001/844/EC [↑](#footnote-ref-6)
6. Any organised collection of data [↑](#footnote-ref-7)
7. A collection of biological material and the associated data and information stored in an organised system, for a population or a large subset of a population. [↑](#footnote-ref-8)
8. A biological specimen including, for example, blood, tissue, urine, etc. taken from a participant. [↑](#footnote-ref-9)
9. A cohort is a group of persons who experience a certain event in a specified period of time. For example, the birth cohort of 1985 would be the people born in that year. [↑](#footnote-ref-10)
10. An application which stores metadata for querying, and which can be used by any other application in the network with sufficient access privileges. [↑](#footnote-ref-11)
11. Programmes, procedures and data associated with the operation of a computer system. [↑](#footnote-ref-12)
12. Any record which can be used to support a scholarly research argument. The term "data" is meant to be broadly inclusive with the exclusion of digital manifestations of text. Data refers to forms of data and databases that are not self-describing -- that require the assistance of metadata, computational machinery and/or software in order to be useful, such as various types of laboratory data including spectrographic, genomic sequencing, and electron microscopy data; observational data; clinical trial data, assay data; as well as other forms of data either generated or compiled by humans or machines. Source: modified from <https://www.force11.org/datacitation> Glossary. [↑](#footnote-ref-13)
13. Linking databases maintained by two organisations in different geographical locations, or simply heterogeneous systems within one organisation that, historically, have not easily interoperated at the data level.
Source: modified from <http://eprints.soton.ac.uk/271285/1/bizer-heath-berners-lee-ijswis-linked-data.pdf> [↑](#footnote-ref-14)
14. A permanent identifier should be a persistent link to the published version full text if open access or abstract if article is pay per view or to the final manuscript accepted for publication (link to article in repository). [↑](#footnote-ref-15)
15. Open Access is defined as free of charge access for anyone via Internet. Please answer "yes" if the open access to the publication is already established and also if the embargo period for open access is not yet over but you intend to establish open access afterwards. [↑](#footnote-ref-16)
16. List of dissemination activity: publications, conferences, workshops, web, press releases, flyers, articles published in the popular press, videos, media briefings, presentations, exhibitions, thesis, interviews, films, TV clips, posters, Other. [↑](#footnote-ref-17)
17. Type of public: Scientific Community (higher education, Research), Industry, Civil Society, Policy makers, Medias, Other ('multiple choices' is possible). [↑](#footnote-ref-18)
18. Please choose the type of IP rights: Patents, Trademarks, Registered designs, Utility models, Trade Secrets, Others. [↑](#footnote-ref-19)
19. Please choose the type of Foreground: General advancement of knowledge, commercial exploitation of R&D results, contribution to the preparation of European or international standards, impact on EU policies, exploitation of results contributing to innovation. [↑](#footnote-ref-20)
20. Please indicate the type sector (NACE nomenclature) : <http://ec.europa.eu/competition/mergers/cases/index/nace_all.html> [↑](#footnote-ref-21)
21. when there is a special clause 13 in the Grant Agreement [↑](#footnote-ref-22)
22. when the non-EU in kind exceeds the maximum limit set in special clause 13 or when there is no special clause 13 in the Grant Agreement [↑](#footnote-ref-23)
23. To be submitted in all cases in final period for EFPIA companies. For beneficiares and linked third parties a CFS is to be submitted in final period unless the below conditions apply:

• During their participation the cumulated IMI JU contribution does not exceed EUR 50.000, or

• In the final reporting period (at the end of the project) or, earlier, when a beneficiary (or a linked third party) is terminating its participation the two following conditions subsist:

 o a CFS has already been submitted by the concerned beneficiary/ linked third party during the lifetime of the project and has been accepted by IMI.

 o the cumulative remaining amounts of IMI contributions and EFPIA receipts received by the beneficiary/ linked third party do not exceed 375.000 EUR, [↑](#footnote-ref-24)